Publications by authors named "Susan Stonehouse-Lee"
Objectives: Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma treated with ipilimumab, a pretreatment neutrophil-to-lymphocyte ratio (NLR)<5 has been associated with improved survival. This retrospective cohort study aimed to determine whether the pretreatment NLR was associated with outcomes in NSCLC patients treated with nivolumab.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates the effectiveness of using cell-free circulating tumor DNA (ctDNA) next-generation sequencing (NGS) as a potential substitute for traditional tissue biopsies in identifying genetic alterations in advanced non-small cell lung cancer (NSCLC).
- Of the 112 plasma samples analyzed, ctDNA NGS detected mutations in 86 out of 102 patients, including significant driver and resistance mutations, which were not always identifiable through tissue samples.
- The findings suggest that ctDNA NGS can reliably identify actionable mutations, aiding in patient diagnosis and treatment management even when tissue samples are limited or unavailable.
Purpose: The purpose of this study was to determine the efficacy and tolerability of carboplatin, pemetrexed, and bevacizumab in patients with advanced, nonsquamous non-small-cell lung cancer (NSCLC).
Patients And Methods: The charts of consecutive patients with stage IIIB/IV nonsquamous NSCLC were reviewed. All patients receiving at least 1 cycle of the 3-drug regimen (pemetrexed 500 mg/m2, carboplatin area under the curve of 5-6, bevacizumab 15 mg/kg intravenously), were included for assessment of response, safety, and toxicity.